ARCA receives European Patent for bucindolol based treatment for heart failure ARCA biopharma, Inc. , a biopharmaceutical business developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced that the European Patent Workplace has issued a patent on ways of treating heart failing patients with bucindolol based on genetic targeting. The patent entitled ‘Options for Treatment with Bucindolol Based on Genetic Targeting,’ provides protection for this novel method of treating patients with heart failure in France, Germany, Netherlands, Switzerland/Liechtenstein, Great Britain, Ireland, Luxembourg, Monaco, Spain, Italy and Sweden.Nunes. This work is specially meaningful for us because it complements our interest in health disparities and highlights the enthusiastic participation of African-Americans in breast tumor research. Unlike genetic tests such as for example those for BRCA genes , genomic tests consider the genes inside a breast tumor cell and how highly they are expressed. The results support prior research that has looked at the biologic features of breast cancer in African-American females, but this type of methodology reported right here was used for the 1st time in this population. Tumor specialists will continue steadily to follow the sufferers in the research study over another five years to evaluate their survival with treatment, according with their gene profile.
Adult stem cells may be beneficial for certain cardiovascular disorders and autoimmune diseases An assessment of previously published study suggests that stem cells harvested from an adult’s blood or marrow might provide treatment benefit to select patients for some autoimmune diseases and cardiovascular disorders, according to an article in the February 27 issue of JAMA: The Journal of the American Medical Association.